- Home
- AMC vs ETNB Comparison
AMC vs ETNB Comparison
Compare AMC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- ETNB
- Stock Information
- Founded
- AMC 1920
- ETNB 2018
- Country
- AMC United States
- ETNB United States
- Employees
- AMC N/A
- ETNB N/A
- Industry
- AMC Movies/Entertainment
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- AMC Consumer Discretionary
- ETNB Health Care
- Exchange
- AMC Nasdaq
- ETNB Nasdaq
- Market Cap
- AMC 1.5B
- ETNB 1.5B
- IPO Year
- AMC 2013
- ETNB 2019
- Fundamental
- Price
- AMC $2.82
- ETNB $9.75
- Analyst Decision
- AMC Hold
- ETNB Strong Buy
- Analyst Count
- AMC 7
- ETNB 8
- Target Price
- AMC $3.92
- ETNB $26.43
- AVG Volume (30 Days)
- AMC 7.5M
- ETNB 2.2M
- Earning Date
- AMC 08-01-2025
- ETNB 08-04-2025
- Dividend Yield
- AMC N/A
- ETNB N/A
- EPS Growth
- AMC N/A
- ETNB N/A
- EPS
- AMC N/A
- ETNB N/A
- Revenue
- AMC $4,548,300,000.00
- ETNB N/A
- Revenue This Year
- AMC $8.36
- ETNB N/A
- Revenue Next Year
- AMC $6.63
- ETNB N/A
- P/E Ratio
- AMC N/A
- ETNB N/A
- Revenue Growth
- AMC N/A
- ETNB N/A
- 52 Week Low
- AMC $2.45
- ETNB $4.16
- 52 Week High
- AMC $5.76
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- AMC 36.88
- ETNB 52.08
- Support Level
- AMC $2.95
- ETNB $9.59
- Resistance Level
- AMC $3.14
- ETNB $10.20
- Average True Range (ATR)
- AMC 0.11
- ETNB 0.51
- MACD
- AMC -0.04
- ETNB -0.12
- Stochastic Oscillator
- AMC 4.24
- ETNB 38.79
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).